Use Cases
Case Studies
No English use case articles yet. Please check back later.
OTHER CASES
Additional Case Studies
Industry-Leading Track Record
Extensive experience across life science fields
Improvement 19 cases
Improvement 12 cases
Reduction 15 cases
Reduction 16 cases
Cell Culture Media Development for Antibody Drug Manufacturing
40% Improvement in Antibody Production
Using CellTune, our culture optimization software powered by Epistra Accelerate, we improved the feed media composition for antibody production. As a result of the optimization, we discovered a media composition that increased antibody production by approximately 40% compared to the pre-optimization composition.
Novel Assay System Construction
46% Improvement in Detection Sensitivity
44% Reduction in R&D Period
We optimized conditions for a novel assay for drug screening. Human researchers and Epistra Accelerate independently conducted the optimization and compared results. The conditions discovered by Epistra Accelerate improved pre-optimization sensitivity by 46% and exceeded human-discovered conditions by 12%. While human researchers took 4.5 months, Epistra Accelerate completed the exploration in 2.5 months, achieving a 44% reduction in R&D time.
Improving Cell Preservation Reagent Performance
133% Improvement in Yield
40% Improvement in Functionality
Robust Against Temperature/Concentration Changes
We developed a higher-performance cell preservation reagent for the commercialization of cell-based therapeutics. Through optimization, we identified a reagent composition that improved yield by 133% and cell functionality by 40% compared to commercially available products. The identified composition is also robust against temperature and concentration variations, while avoiding third-party intellectual property.
Culture Media Cost Reduction
70% Cost Reduction
Culture media costs for pharmaceutical manufacturing are high. We undertook an initiative to minimize media costs while maintaining comparable performance to improve profitability. Through optimization, we achieved a 70% reduction in total media costs, with projected ongoing savings of over 400 million yen per year.
Animal Origin-Free (AOF) Medium Development
Significant Yield Improvement
Achieved AOF
We optimized the media composition for the client's mesenchymal stem cells (MSC) using Epistra Accelerate. After 4 months of condition screening, we discovered a media composition with superior proliferative capacity and significantly reduced raw material costs. All media developed in this project are animal origin-free (AOF), containing no animal or human-derived factors.
PAST RESULTS
Track Record
Applicable to a Wide Range of Use Cases
Antibody
Drugs
Cryopreservation
Solutions
Chemically
Defined Media
Regenerative
Medicine
Bio-
manufacturing
Vaccine
Manufacturing
Breeding
Assay
Development